MRNA:OTCQB-Marina Biotech Inc (USD)

COMMON STOCK | Biotechnology | OTCQB - U.S. Registered

Last Closing

USD 129.06

Change

+0.74 (+0.58)%

Market Cap

USD 0.02B

Volume

2.94M

Analyst Target

USD 89.73
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Marina Biotech Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+4.72 (+1.00%)

USD 121.32B
REGN Regeneron Pharmaceuticals Inc

-4.54 (-0.49%)

USD 103.77B
ALNY Alnylam Pharmaceuticals Inc

-3.20 (-1.12%)

USD 36.83B
ARGX argenx NV ADR

-1.17 (-0.21%)

USD 33.21B
BGNE BeiGene Ltd

-10.54 (-4.87%)

USD 24.57B
RPRX Royalty Pharma Plc

+0.04 (+0.15%)

USD 16.47B
UTHR United Therapeutics Corporatio..

+8.60 (+2.44%)

USD 15.69B
SMMT Summit Therapeutics PLC

-3.18 (-14.57%)

USD 15.13B
PCVX Vaxcyte Inc

+0.55 (+0.52%)

USD 13.95B
BMRN Biomarin Pharmaceutical Inc

-3.23 (-4.62%)

USD 13.32B

ETFs Containing MRNA

MRN3:LSE Leverage Shares 3x Long M.. 300.15 % 0.00 %

-0.04 (0.42%)

USD 0.36M
MSGR 6.26 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 5.70 % 0.00 %

-0.06 (0.42%)

N/A
HVAX:CA 4.95 % 0.00 %

N/A

N/A
BTEC:SW iShares Nasdaq US Biotech.. 4.67 % 0.00 %

N/A

N/A
CURG:LSE VanEck Genomics and Healt.. 4.37 % 0.00 %

+0.06 (+0.42%)

USD 5.12M
LS:CA 3.47 % 2.21 %

N/A

N/A
XNNV:XETRA Xtrackers MSCI Innovation.. 3.03 % 0.00 %

-0.19 (0.42%)

N/A
XNNS:LSE Xtrackers MSCI Innovation.. 3.01 % 0.00 %

+0.04 (+0.42%)

N/A
XNNV:LSE Xtrackers MSCI Innovation.. 3.01 % 0.00 %

+0.04 (+0.42%)

N/A
ASRP:XETRA BNP Paribas Easy ECPI Glo.. 2.69 % 0.00 %

-0.07 (0.42%)

N/A
IBBQ Invesco Nasdaq Biotechnol.. 2.06 % 0.00 %

-0.11 (0.42%)

USD 0.04B
2B70:XETRA iShares Nasdaq US Biotech.. 2.04 % 0.00 %

-0.02 (0.42%)

USD 0.52B
2B70:F iShares NASDAQ US Biotech.. 2.04 % 0.00 %

N/A

USD 0.52B
ZUH:CA BMO Equal Weight US Healt.. 1.68 % 0.39 %

+0.10 (+0.42%)

CAD 0.26B
ZHU:CA BMO Equal Weight US Healt.. 1.68 % 0.00 %

+0.05 (+0.42%)

CAD 0.01B
FCTR 1.68 % 0.00 %

N/A

N/A
TAEQ 1.46 % 0.00 %

N/A

N/A
BIB ProShares Ultra Nasdaq Bi.. 1.43 % 0.95 %

-0.61 (0.42%)

USD 0.09B
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

-0.01 (0.42%)

USD 2.57B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

+1.40 (+0.42%)

N/A
FLAG 0.00 % 1.52 %

N/A

N/A
BTEC 0.00 % 0.42 %

N/A

N/A
HWF:CA 0.00 % 0.00 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.03 (+0.42%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.02 (+0.42%)

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.03 (+0.42%)

N/A
RYH 0.00 % 0.40 %

N/A

N/A
XT iShares Exponential Techn.. 0.00 % 0.47 %

-0.93 (0.42%)

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
MRNS:LSE -299.96 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (OTCQB - U.S. Registered)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 29.75% 75% C 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.75% 75% C 85% B
Trailing 12 Months  
Capital Gain 2.78% 66% D+ 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.78% 66% D+ 48% F
Trailing 5 Years  
Capital Gain 459.19% 95% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 459.19% 95% A 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 137.48% 94% A 96% N/A
Dividend Return 137.48% 94% A 96% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 221.86% 12% F 7% C-
Risk Adjusted Return 61.96% 97% N/A 87% B+
Market Capitalization 0.02B 100% F 98% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector